AbbVie (ABBV) Stock Gets Fair Value Bump After Analyst Target Increases

AbbVie’s analyst narrative has shifted again, with fair value in one model now set at US$284.79 compared with US$278.61 previously, and other price targets clustering in a wide US$260 to US$325 range. Recent commentary links these higher targets to confidence in AbbVie’s portfolio across immunology, neuroscience and oncology, while still flagging risks around specific programs and crowded positioning. As you read on, you will see how to interpret these moving targets and track the story as it...